Popular
Latest Articles
Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne
Ractigen Therapeutics has presented positive first-in-human data for RAG-18...
Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data
Entrada Therapeutics’ ENTR-601-44 is an investigational therapy designed for...
NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping
NS Pharma’s brogidirsen (NS-089/NCNP-02) is an investigational therapy for...
Most Popular
Frequently Asked Questions About Elevidys Used for DMD
Duchenne muscular dystrophy (DMD) is a genetic condition that...
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
The landscape of potential new gene therapies for Duchenne...
The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control
The duchenne muscular dystrophy treatment cost has become one...
© 2024 - 2026 DMD Warrior. All rights reserved.